Fetal arrhythmia during treatment of pregnancy-associated acute promtelocytic leukemia with all-trans retinoic acid and favorable outcome

Terada, Yukihiro; Shindo, Toru; Endoh, Akira; Watanabe, Maya; Fukaya, Takao; Yajima, Akira

doi:10.1038/sj.leu.2400595

Cited by 53 publications

(20 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, close fetal cardiac monitoring to unravel complications has been strongly recommended throughout the pregnancy because some cases of reversible cardiac arrhythmia were reported. 42,43 By contrast, although there is scarce information regarding the teratogenicity of ATRA, its use during the first trimester of pregnancy is not recommended because retinoids are known teratogenics.…”

Section: Management Of Pregnant Patients With Aplmentioning

confidence: 99%

Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia

Sanz

Tallman

Lo‐Coco

2005

Blood

114

View full text Add to dashboard Cite

Section: Management Of Pregnant Patients With Aplmentioning

confidence: 99%

Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia

Sanz

Tallman

Lo‐Coco

2005

Blood

114

View full text Add to dashboard Cite

“…Although the experience is quite limited, there were no fetal malformations reported suggestive of retinoic acid embryopathy. 111 However, because some cases of reversible fetal arrhythmias and other cardiac complications at birth have been reported, 114,115 stringent fetal monitoring, with particular emphasis on cardiac function, is recommended for patients receiving ATRA alone or combined with chemotherapy during pregnancy.…”

Section: Management Of Apl During the First Trimester Of Pregnancymentioning

confidence: 99%

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Sanz

Grimwade

Tallman

et al. 2009

Blood

863

732

View full text Add to dashboard Cite

The introduction of all-trans retinoic acid (ATRA) and, more recently, arsenic trioxide (ATO) into the therapy of acute promyelocytic leukemia (APL) has revolutionized the management and outcome of this disease. Several treatment strategies using these agents, usually in combination with chemotherapy, but also without or with minimal use of cytotoxic agents, have provided excellent therapeutic results. Cure of APL patients, however, is also dependent on peculiar aspects related to the management and supportive measures that are crucial to counteract life-threatening complications associated with the disease biology and molecularly targeted treatment. The European LeukemiaNet recently appointed an international panel of experts to develop evidence-and expert opinion-based guidelines on the diagnosis and management of APL. Together with providing current indications on genetic diagnosis, modern risk-adapted front-line therapy and salvage treatment, the review contains specific recommendations for the identification and management of most important complications such as the bleeding disorder, APL differentiation syndrome, QT prolongation and other ATRAand ATO-related toxicities, as well as for molecular assessment of response to treatment. Finally, the approach to special situations is also discussed, including management of APL in children, elderly patients, and pregnant women.

show abstract

“…As ATRA therapy in pregnancy has been associated with fetal cardiac toxicity including reversible arrhythmias, the importance of cardiac monitoring should be highlighted. 3,13,37 In consultation with obstetric colleagues, elective delivery can be scheduled according to fetal maturity and a gestational age of 32 weeks or more is usually acceptable. Antenatal corticosteroids before preterm delivery are recommended to alleviate the complications of respiratory distress syndrome.…”

Section: Aplmentioning

confidence: 99%

How I treat leukemia during pregnancy

Milojković

Apperley

2014

Blood

123

View full text Add to dashboard Cite

Leukemia in pregnancy remains a challenging therapeutic prospect. The prevalence is low at ∼1 in 10 000 pregnancies, and as a result data are limited to small retrospective series and case reports, rendering evidence-based recommendations for management strategies difficult. The management of the leukemias in pregnancy requires close collaboration with obstetric and neonatology colleagues as both the maternal and fetal outcomes must be taken into consideration. The decision to introduce or delay chemotherapy must be balanced against the impact on maternal and fetal survival and morbidity. Invariably, acute leukemia diagnosed in the first trimester necessitates intensive chemotherapy that is likely to induce fetal malformations. As delaying treatment in this situation is usually inappropriate, counseling with regard to termination of pregnancy is often essential.For chronic disease and acute leukemia diagnosed after the second trimester, therapeutic termination of the pregnancy is not inevitable and often, standard management approaches similar to those in nongravid patients can be used. Here, the management of the acute and chronic leukemias will be addressed. (Blood. 2014;123(7):974-984)

show abstract

Fetal arrhythmia during treatment of pregnancy-associated acute promtelocytic leukemia with all-trans retinoic acid and favorable outcome

Cited by 53 publications

References 1 publication

Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia

Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

How I treat leukemia during pregnancy

Contact Info

Product

Resources

About